Santhera Pharmaceuticals Holding AG
SANN
Rang in Aktien
#16591
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Aktienkurs
$17.23
Marktkapitalisierung
$263.68M
Veränderung (1 Tag)
-4.18%
Veränderung (1 Jahr)
38.54%
Land
CH
Handel Santhera Pharmaceuticals Holding AG (SANN)
Kategorie
Healthcare
Kursverlauf für Santhera Pharmaceuticals Holding AG (SANN)
Höchster Schlusskurs: $18.92 am 2026-10-01
Niedrigster Schlusskurs: $44.13 am 2014-03-01
Niedrigster Schlusskurs: $44.13 am 2014-03-01
Kursverlauf der Aktie von Santhera Pharmaceuticals Holding AG von 2014 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 22.24% |
| 2025 | 42.98% |
| 2024 | -6.16% |
| 2023 | 41.12% |
| 2022 | -43.82% |
| 2021 | -53.14% |
| 2020 | -74.39% |
| 2019 | -17.31% |
| 2018 | -49.89% |
| 2017 | -38.99% |
| 2016 | -48.52% |
| 2015 | -16.32% |
| 2014 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $535.97 | 25.69% |
US
|
|
| $190.72 | 610.32% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $889.32 | 9.23% |
NL
|
